LY3556050   Click here for help

GtoPdb Ligand ID: 13682

Synonyms: Example 47 [WO2014184275A1] | Example XLVII [WO2014184275A1] | LY-3556050 | mazisotine
Compound class: Synthetic organic
Comment: LY3556050 is a non-peptide somatostatin receptor subtype 4 (SST4) receptor agonist [1].
SST4 is expressed by peripheral sensory neurons and SST4-mediated antinociception is being pursued as a promising mechanism for non-opioid pain relief.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 62.72
Molecular weight 289.37
XLogP 0.27
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC=CN=C1OCC(C)(C)NC(=O)C2[C@H]3CNC[C@H]32
Isomeric SMILES CC1=C(N=CC=C1)OCC(C)(C)NC(=O)C2[C@H]3[C@@H]2CNC3
InChI InChI=1S/C16H23N3O2/c1-10-5-4-6-18-15(10)21-9-16(2,3)19-14(20)13-11-7-17-8-12(11)13/h4-6,11-13,17H,7-9H2,1-3H3,(H,19,20)/t11-,12+,13?
InChI Key PCINBSQTEDBZDB-FUNVUKJBSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
LY3556050 is a clinical candidate. It is being investigated for analgesic potential.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06074562 A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2 Interventional Eli Lilly and Company
NCT05986292 A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain Phase 2 Interventional Eli Lilly and Company
NCT04627038 Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis Phase 2 Interventional Eli Lilly and Company
NCT04874636 Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain Phase 2 Interventional Eli Lilly and Company